Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

The two largest leases in Boston-Cambridge's life science market went to Korro Bio and Ultragenyx Pharmaceuticals, which ...

Any remaining cloud early in the night will tend to clear away. The rest of the night will continue cold and widely clear under a light to gentle north-westerly breeze. Thursday Tomorrow will see ...

But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

It’s not just seafood and Italian in the greater Boston area. There’s great Vietnamese, omakase, Peruvian and even bagels worth seeking out. (Don’t worry, there’s also great seafood and ...

The EMBOLD study of relutrigine is progressing ... were shared during the Praxis scientific exhibit at the December 2024 American Epilepsy Society (AES) Annual Meeting. The RADIANT Phase 2 study ...

It’s always the start, middle, or end of some sports season around here, and plenty of Boston bars and restaurants are ready and waiting with beer, wings, and televisions. Here are 15 of the best ...

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s ...

Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. The smooth upward movement of the stock indicates the quality of its investor base.